16:12 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV) In vitro , cell culture, rat and dog studies identified a CYPA inhibitor that could help treat HCV. Chemical synthesis of analogs of the natural product sanglifehrin A and in...
17:57 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Patient sample, rat and mouse studies suggest inhibiting CYPA could help treat ALS. Levels of CYPA were higher in CSF from sporadic ALS patients, a mouse model of familial ALS...
21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV); HIV/AIDS; coronavirus; viral infection Cell culture and in vitro studies identified phenylpyrrolidine-based inhibitors of CYPA , CYPB and CYPD that could help treat HCV, HIV/AIDS, coronavirus and other viral infections....
07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Ciclofilin, ContraVir Pharmaceuticals deal

ContraVir acquired fellow HBV company Ciclofilin for up to $17 million in development and regulatory milestones related to Ciclofilin’s CPI-431-32 . ContraVir said CPI-431-32 might “someday” be used in combination with its HBV candidate CMX157...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Ciclofilin preclinical data

In a mouse model of liver fibrosis, oral CP-431-32 for 21 days reduced fibrosis by about 55% from baseline to day 21 vs. controls (p<0.01). The cyclophilin A ( CYPA ; PPIA ) antagonist was...
08:00 , Dec 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Ischemia/reperfusion injury; renal damage Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); cyclophilin A (CYPA; PPIA) Mouse studies suggest the ferrostatin 16-86 could help protect against ischemia/reperfusion...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Cleavage and polyadenylation specific factor 6 (CPSF6); cyclophilin A (CYPA; PPIA) Cell culture studies suggest blocking interaction between HIV capsid protein and host...
07:00 , Sep 17, 2012 |  BioCentury  |  Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen...
07:00 , Jun 14, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Cyclophilin A (CYPA; PPIA) Mouse studies suggest antagonizing PPIA could be useful for treating AD. In mice with the AD-associated E4 allele...
08:00 , Jan 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Apolipoprotein E (APOE); cyclophilin A (PPIA; CYPA) Studies in mice suggest that inhibiting PPIA could help treat atherosclerosis. In...